Altered Th17/Treg Ratio in Peripheral Blood of Systemic Lupus Erythematosus but Not Primary Antiphospholipid Syndrome

被引:46
|
作者
Alvarez-Rodriguez, Lorena [1 ]
Martinez-Taboada, Victor [2 ]
Calvo-Alen, Jaime [3 ]
Beares, Inaki [1 ]
Villa, Ignacio [4 ]
Lopez-Hoyos, Marcos [5 ]
机构
[1] Univ Hosp Marques de Valdecilla IDIVAL, Rheumatol Dept, Transplantat & Autoimmun Lab, Santander, Spain
[2] Cantabria Univ, Univ Hosp Marques de Valdecilla IDIVAL, Rheumatol Dept, Fac Med, Santander, Spain
[3] Univ Hosp Araba, Rheumatol Dept, Vitoria, Spain
[4] Hosp Sierrallana, Rheumatol Dept, Torrelavega, Spain
[5] Cantabria Univ, Univ Hosp Marques de Valdecilla IDIVAL, Immunol Dept, Santander, Spain
来源
FRONTIERS IN IMMUNOLOGY | 2019年 / 10卷
关键词
pAPS; SLE; Th1; Th17; Treg; inflammation; REGULATORY T-CELLS; CLASSIFICATION CRITERIA; PATHOGENESIS; ATHEROSCLEROSIS; EXPRESSION; RESPONSES; IMMUNITY; DISEASE;
D O I
10.3389/fimmu.2019.00391
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: The role of the immune response in the pathogenesis of antiphospholipid syndrome (APS) remains elusive. It is possible that differences in the frequencies of Th17 cells and/or defects in the immunoregulatory mechanisms are involved in the pathogenesis of APS. Our aim was to determine the peripheral blood Th cells phenotype and the circulating cytokine profile in patients with primary APS (pAPS) and compare it with systemic lupus erythemathosus (SLE) as disease control group. Methods: The frequencies of circulating regulatory T cells (Tregs) were determined in PBMCs from 36 patients with pAPS by flow cytometry. As control groups we included 21 age-and gender-matched healthy controls (HC) and 11 patients with SLE. The suppressive capacity of Tregs was evaluated in vitro by coculture assay. On the other hand, intracellular cytokine production was assessed in Th1, Th2, and Th17 cells and circulating IL-6, IL-10, and IL-35 were measured by Cytometric Bead Array and ELISA. The quantification of Th master gene expression levels was performed by real time quantitative PCR. Results: pAPS patients and SLE patients did not show differences in the percentage or number of Tregs compared to HC. The suppressive capacity of Tregs was also similar in the three study group. Instead, we found higher FoxP3.mRNA expression levels in pAPS patients and HC than SLE patients. Regarding the Th17 response, patients with pAPS and HC showed a significantly lower frequency of circulating Th17 cells than SLE. However, no differences were observed in the Th1 response between patients and controls. Thus, increased Th17/Th1 and Th17/Treg ratios were found in SLE patients but not in pAPS patients. pAPS and SLE patients had higher serum IL-6 levels than HC but there was not difference between both disease groups. Besides, a significant increase in the immunosuppressive cytokine levels was observed only in pAPS as compared to HC. Conclusions: Our data demonstrate an increased inflammatory profile of peripheral blood CD4(+) T cells from SLE as compared with pAPS mostly due to an increased Th17 response. In conclusion, there seems not to be a direct pathogenic role for Th cells in pAPS but in SLE.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Primary hyperparathyroidism in a patient with systemic lupus erythematosus-antiphospholipid syndrome
    Benekli, M
    Savas, MC
    Erdem, Y
    Yalçin, AU
    Yasavul, Ü
    Turgan, Ç
    Çaglar, S
    NEPHRON, 1998, 79 (02): : 215 - 216
  • [42] Primary antiphospholipid syndrome progressing to systemic lupus erythematosus: a case report
    Manganelli, Rocco
    Iannaccone, Salvatore
    De Simone, Walter
    ITALIAN JOURNAL OF MEDICINE, 2010, 4 (02) : 116 - 121
  • [43] Antiphospholipid Antibodies and Atherosclerosis: Insights from Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome
    Paul R. J. Ames
    Annamaria Margarita
    Jose Delgado Alves
    Clinical Reviews in Allergy & Immunology, 2009, 37 : 29 - 35
  • [44] Antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome
    Salcido-Ochoa, F
    Cabiedes, J
    Alarcón-Segovia, D
    Cabral, AR
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2002, 8 (05) : 251 - 255
  • [45] Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome
    Jiménez, S
    García-Criado, MA
    Tàssies, D
    Reverter, JC
    Cervera, R
    Gilabert, MR
    Zambón, D
    Ros, E
    Bru, C
    Font, J
    RHEUMATOLOGY, 2005, 44 (06) : 756 - 761
  • [46] Blood nitrates content in patients with systemic lupus erythematosus and antiphospholipid syndrome
    Reshetnyak, DV
    Kuznetsova, TV
    Kobylyansky, AG
    Klyukvina, NG
    Reshetnyak, TM
    Nasonov, EL
    TERAPEVTICHESKII ARKHIV, 2004, 76 (05): : 19 - 22
  • [47] Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus
    Yang, Ji
    Yang, Xue
    Yang, Jie
    Li, Ming
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (06) : 818 - 826
  • [48] The antiphospholipid syndrome in patients with systemic lupus erythematosus
    Pons-Estel, Guillermo J.
    Andreoli, Laura
    Scanzi, Francesco
    Cervera, Ricard
    Tincani, Angela
    JOURNAL OF AUTOIMMUNITY, 2017, 76 : 10 - 20
  • [49] Editorial: Systemic Lupus Erythematosus and Antiphospholipid Syndrome
    Meroni, Pier Luigi
    Tsokos, George C.
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [50] ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC LUPUS-ERYTHEMATOSUS
    ANDREWS, PA
    FRAMPTON, G
    CAMERON, JS
    LANCET, 1993, 342 (8877): : 988 - 989